Skip to main content

Advertisement

SpringerLink
Log in

Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Renal inflammation is a final common pathway of chronic kidney disease (CKD), and its progression can be used to effectively gauge the degree of renal dysfunction. Interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK-4) has been reported to be a pivotal molecule for IL-1 receptor- and Toll-like receptor-induced signaling and activation of proinflammatory mediators. In this study, we hypothesized that if inflammation plays a key role in renal failure, then the anti-inflammatory effect of IRAK-4 inhibitor should be effective in improving CKD. To determine its pharmacological potency, we investigated the renoprotective properties of the novel IRAK-4 inhibitor AS2444697 (N-[3-carbamoyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide hydrochloride (1:1)) in 5/6 nephrectomized (Nx) rats, a model of CKD. Six weeks’ repeated administration of AS2444697 (0.3–3 mg/kg, twice daily) dose-dependently and significantly reduced urinary protein excretion and prevented the development of glomerulosclerosis and interstitial fibrosis without affecting the blood pressure. In addition, AS2444697 showed beneficial effects on renal function as demonstrated by the decrease in levels of plasma creatinine and blood urea nitrogen and attenuation of decline in creatinine clearance. 5/6 Nx rats exhibited low-grade inflammation as evidenced by increased renal mRNA expression and plasma levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α, and MCP-1) and C-reactive protein as a marker of systemic inflammation. AS2444697 significantly reduced or showed a decreasing trend in expression and levels of these inflammatory parameters. These results suggest that AS2444697 suppresses the progression of chronic renal failure via anti-inflammatory action and may therefore be potentially useful in treating CKD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  • Carrero JJ, Stenvinkel P (2009) Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 4:S49–55

    Article  PubMed  CAS  Google Scholar 

  • Cho ME, Kopp JB (2010) Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs 19:275–283

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuler L, Newman A (2004) Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15:3184–3191

    Article  PubMed  Google Scholar 

  • Ghosh SS, Krieg R, Massey HD, Sica DA, Fakhry I, Ghosh S, Gehr TW (2012) Curcumin and enalapril ameliorate renal failure by antagonizing inflammation in 5/6 nephrectomized rats: role of phospholipase and cyclooxygenase. Am J Physiol Renal Physiol 15:F439–454

    Article  Google Scholar 

  • Imanishi J, Ishikawa T, Imamura E, Mizuhara H, Iwaoka H, Evelyn B, Inami H, Mizutani T, Watanabe J, Usuda H, Nagashima S, Ito T, Kontani T, Shimizu Y, Mutoh S (2011) Anti-inflammatory profile of AS2444697, a novel interleukin-1 receptor-associated kinase-4 inhibitor. Arthritis Rheum 63:S390

    Google Scholar 

  • Inami H, Mizutani T, Watanabe J, Usuda H, Nagashima S, Ito T, Aoyama N, Kontani T, Hayashida H, Terasawa T, Moritomo A, Ishikawa T, Hayashi K, Takeuchi M, Ohta M (2011) Oxazolecarboxamide derivatives as novel IRAK-4 inhibitors. 242nd ACS National Meeting & Exposision, MEDI 329.

  • Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47:1285–1294

    Article  PubMed  CAS  Google Scholar 

  • Kim TW, Staschke K, Bulek K, Yao J, Peters K, Oh KH, Vandenburg Y, Xiao H, Qian W, Hamilton T, Min B, Sen G, Gilmour R, Li X (2007) A critical role for IRAK-4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 14:1025–1036

    Article  Google Scholar 

  • Kim HJ, Vaziri ND, Norris K, An WS, Quiroz Y, Rodriguez-Iturbe B (2010) High-calorie diet with moderate protein restriction prevents cachexia and ameliorates oxidative stress, inflammation and proteinuria in experimental chronic kidney disease. Clin Exp Nephrol 14:536–547

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J (1996) Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49:666–678

    Article  PubMed  CAS  Google Scholar 

  • Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, Chrabieh M, Issekutz AC, Cunningham CK, Gallin J, Holland SM, Roifman C, Ehl S, Smart J, Tang M, Barrat FJ, Levy O, McDonald D, Day-Good NK, Miller R, Takada H, Hara T, Al-Hajjar S, Al-Ghonaium A, Speert D, Sanlaville D, Li X, Geissmann F, Vivier E, Marodi L, Garty BZ, Chapel H, Rodriguez-Gallego C, Bossuyt X, Abel L, Puel A, Casanova JL (2007) Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 204:2407–2422

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Lambers Heerspink HJ, de Zeeuw D (2013) Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 76:536–550

    PubMed  CAS  Google Scholar 

  • Lebleu VS, Sugimoto H, Miller CA, Gattone VH 2nd, Kalluri R (2008) Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab Invest 88:284–292

    Article  PubMed  CAS  Google Scholar 

  • Li S, Strelow A, Fontana EJ, Wesche H (2002) IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A 16:5567–5572

    Article  Google Scholar 

  • Lin M, Tang SC (2013) Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol Dial Transplant 0:1–11

  • Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS (2005) The renoprotective potential of pentoxifylline in chronic kidney disease. J Chin Med Assoc 68:99–105

    Article  PubMed  CAS  Google Scholar 

  • Lopez-Novoa JM, Martinez-Salgado C, Rodriguez-Pena AB, Lopez-Hernandez FJ (2010) Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives. Pharmacol Ther 128:61–81

    Article  PubMed  CAS  Google Scholar 

  • Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, Arditi M, Gallin JI, Vogel SN (2003) Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 18:521–531

    Article  Google Scholar 

  • Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65:1009–1016

    Article  PubMed  Google Scholar 

  • Ortega LM, Fornoni A (2010) Role of cytokines in the pathogenesis of acute and chronic kidney disease, glomerulonephritis, and end-stage kidney disease. Int J Interf Cytokine Mediat Res 2:49–62

    Article  Google Scholar 

  • Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA (1994) Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45:890–896

    Article  PubMed  CAS  Google Scholar 

  • Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jummah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, Casanova JL (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 28:2076–2079

    Article  Google Scholar 

  • Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F (2013) IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. J Nephrol 26:86–93

    Article  PubMed  CAS  Google Scholar 

  • Silverstein DM (2009) Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24:1445–1452

    Article  PubMed  Google Scholar 

  • Suliman ME, Stenvinkel P (2008) Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transpl 19:329–345

    PubMed  Google Scholar 

  • Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 18:750–756

    Article  Google Scholar 

  • Uehara Y, Kawabata Y, Shirahase H, Wada K, Hashizume Y, Morishita S, Numabe A, Iwai J, Matsuoka H, Sugimoto T (1992) Radical scavenging properties of indapamide and renal protection in Dahl salt-sensitive rats. Hypertens Res 15:17–26

    Article  CAS  Google Scholar 

  • Wang Z, Wesche H, Stevens T, Walker N, Yeh WC (2009) IRAK-4 inhibitors for inflammation. Curr Top Med Chem 9:724–737

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors thank Drs. Wataru Uchida and Shinichi Tsukamoto (Astellas Pharma Inc.) for their valuable comments and continuing encouragement.

Conflict of interest

The authors do not have any conflict of interest.

Author information

Authors and Affiliations

  1. Drug Discovery Research, Astellas Pharma Inc, 21 Miyukigaoka Tsukuba, Ibaraki, 305-8585, Japan

    Mitsuhiro Kondo, Atsuo Tahara, Kazumi Hayashi, Masaki Abe, Hiroshi Inami, Takeshi Ishikawa, Hiroyuki Ito & Yuichi Tomura

Authors
  1. Mitsuhiro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsuo Tahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazumi Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaki Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Inami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuichi Tomura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atsuo Tahara.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kondo, M., Tahara, A., Hayashi, K. et al. Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats. Naunyn-Schmiedeberg's Arch Pharmacol 387, 909–919 (2014). https://doi.org/10.1007/s00210-014-1023-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-014-1023-z

Keywords

Search

Navigation